• +1-646-491-9876
    • +91-20-67278686

    Search

    Anthrax - Pipeline Review, H1 2017

    Anthrax - Pipeline Review, H1 2017

    • Report Code ID: RW0001689420
    • Category Healthcare
    • No. of Pages 142
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Anthrax - Pipeline Review, H1 2017, provides an overview of the Anthrax (Infectious Disease) pipeline landscape.

    Anthrax is a serious infectious disease caused by Bacillus anthracis. Signs and symptoms include nausea, vomiting, abdominal pain, headache, loss of appetite, fever, severe, bloody diarrhea in the later stages of the disease, sore throat and difficulty swallowing. Risk factors include inject illegal drugs, handle animal skins and work in veterinary medicine, especially dealing with livestock.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Anthrax - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Anthrax (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Anthrax (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 24 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

    Anthrax (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Anthrax (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Anthrax (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Anthrax (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Anthrax (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Anthrax (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Anthrax (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Anthrax (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 6
    Publisher Report Coverage 6
    Anthrax - Overview 7
    Anthrax - Therapeutics Development 8
    Pipeline Overview 8
    Pipeline by Companies 9
    Pipeline by Universities/Institutes 12
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    Anthrax - Therapeutics Assessment 17
    Assessment by Target 17
    Assessment by Mechanism of Action 19
    Assessment by Route of Administration 21
    Assessment by Molecule Type 23
    Anthrax - Companies Involved in Therapeutics Development 25
    Altimmune Inc 25
    Aphios Corp 25
    Aradigm Corp 26
    AtralCipan 26
    ContraFect Corp 27
    Crestone Inc 27
    Dynavax Technologies Corp 28
    Emergent BioSolutions Inc 28
    GlaxoSmithKline Plc 29
    Green Cross Corp 29
    Grifols SA 30
    Hawaii Biotech Inc 30
    iBio Inc 31
    Merck & Co Inc 31
    Microbiotix Inc 32
    NanoBio Corp 32
    Paratek Pharmaceuticals Inc 33
    PaxVax Inc 33
    Pfenex Inc 34
    PharmAthene Inc 34
    Planet Biotechnology Inc 35
    Protein Potential LLC 35
    ProThera Biologics Inc 36
    Soligenix Inc 36
    Syntiron LLC 37
    Tetraphase Pharmaceuticals Inc 37
    VLP Biotech Inc 38
    Anthrax - Drug Profiles 39
    anthrax (virus like particles) vaccine - Drug Profile 39
    anthrax + plague vaccine - Drug Profile 40
    anthrax vaccine - Drug Profile 41
    anthrax vaccine - Drug Profile 43
    anthrax vaccine - Drug Profile 44
    anthrax vaccine - Drug Profile 45
    anthrax vaccine - Drug Profile 46
    anthrax vaccine - Drug Profile 47
    Antisense RNAi Oligonucleotide to Inhibit ANTXR1 and ANTXR2 for Anthrax - Drug Profile 48
    ARD-3100 - Drug Profile 49
    AV-7909 - Drug Profile 53
    BDM-I - Drug Profile 55
    CF-306 - Drug Profile 58
    CF-307 - Drug Profile 59
    CF-308 - Drug Profile 60
    ciprofloxacin hydrochloride - Drug Profile 61
    CPN-1311 - Drug Profile 62
    DPX-Anthrax - Drug Profile 63
    DV-230 - Drug Profile 65
    Epimerox - Drug Profile 66
    EV-035 - Drug Profile 67
    GC-1109 - Drug Profile 69
    gepotidacin mesylate - Drug Profile 70
    GREANX - Drug Profile 73
    KKL-35 - Drug Profile 74
    Marinus - Drug Profile 75
    Monoclonal Antibody for Anthrax - Drug Profile 76
    Monoclonal Antibody for Anthrax - Drug Profile 77
    Monoclonal Antibody to Inhibit Anthrax Protective Antigen for Anthrax - Drug Profile 78
    Nasoshield - Drug Profile 79
    omadacycline tosylate - Drug Profile 81
    PBI-220 - Drug Profile 88
    Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile 90
    Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 91
    Px-563L - Drug Profile 93
    Px-563L Second Generation - Drug Profile 95
    raxibacumab - Drug Profile 96
    RiVax + SGX-204 - Drug Profile 97
    rPA-01 - Drug Profile 98
    RPA-563 - Drug Profile 99
    Small Molecule to Inhibit DNA Helicase for Infectious Diseases - Drug Profile 100
    Small Molecule to Inhibit Enoyl-Reductase for Anthrax and Tularaemia - Drug Profile 101
    Small Molecules for Bacterial Infections, Skin Infections and Bone Disorders - Drug Profile 102
    Small Molecules to Inhibit Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 103
    Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 104
    Small Molecules to Inhibit Lethal Factor for Anthrax and Cystic Fibrosis - Drug Profile 106
    Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile 107
    solithromycin - Drug Profile 108
    TP-271 - Drug Profile 121
    Anthrax - Dormant Projects 123
    Anthrax - Discontinued Products 126
    Anthrax - Product Development Milestones 127
    Featured News & Press Releases 127
    Appendix 137
    Methodology 137
    Coverage 137
    Secondary Research 137
    Primary Research 137
    Expert Panel Validation 137
    Contact Us 137
    Disclaimer 138

    List of Tables

    Number of Products under Development for Anthrax, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Anthrax - Pipeline by Altimmune Inc, H1 2017
    Anthrax - Pipeline by Aphios Corp, H1 2017
    Anthrax - Pipeline by Aradigm Corp, H1 2017
    Anthrax - Pipeline by AtralCipan, H1 2017
    Anthrax - Pipeline by ContraFect Corp, H1 2017
    Anthrax - Pipeline by Crestone Inc, H1 2017
    Anthrax - Pipeline by Dynavax Technologies Corp, H1 2017
    Anthrax - Pipeline by Emergent BioSolutions Inc, H1 2017
    Anthrax - Pipeline by GlaxoSmithKline Plc, H1 2017
    Anthrax - Pipeline by Green Cross Corp, H1 2017
    Anthrax - Pipeline by Grifols SA, H1 2017
    Anthrax - Pipeline by Hawaii Biotech Inc, H1 2017
    Anthrax - Pipeline by iBio Inc, H1 2017
    Anthrax - Pipeline by Merck & Co Inc, H1 2017
    Anthrax - Pipeline by Microbiotix Inc, H1 2017
    Anthrax - Pipeline by NanoBio Corp, H1 2017
    Anthrax - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
    Anthrax - Pipeline by PaxVax Inc, H1 2017
    Anthrax - Pipeline by Pfenex Inc, H1 2017
    Anthrax - Pipeline by PharmAthene Inc, H1 2017
    Anthrax - Pipeline by Planet Biotechnology Inc, H1 2017
    Anthrax - Pipeline by Protein Potential LLC, H1 2017
    Anthrax - Pipeline by ProThera Biologics Inc, H1 2017
    Anthrax - Pipeline by Soligenix Inc, H1 2017
    Anthrax - Pipeline by Syntiron LLC, H1 2017
    Anthrax - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
    Anthrax - Pipeline by VLP Biotech Inc, H1 2017
    Anthrax - Dormant Projects, H1 2017
    Anthrax - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Anthrax - Dormant Projects, H1 2017 (Contd..2), H1 2017
    Anthrax - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Anthrax, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Altimmune Inc
    Aphios Corp
    Aradigm Corp
    AtralCipan
    ContraFect Corp
    Crestone Inc
    Dynavax Technologies Corp
    Emergent BioSolutions Inc
    GlaxoSmithKline Plc
    Green Cross Corp
    Grifols SA
    Hawaii Biotech Inc
    iBio Inc
    Merck & Co Inc
    Microbiotix Inc
    NanoBio Corp
    Paratek Pharmaceuticals Inc
    PaxVax Inc
    Pfenex Inc
    PharmAthene Inc
    Planet Biotechnology Inc
    Protein Potential LLC
    ProThera Biologics Inc
    Soligenix Inc
    Syntiron LLC
    Tetraphase Pharmaceuticals Inc
    VLP Biotech Inc

    Request for Sample

    Report Url http://www.reportsweb.com//anthrax-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//anthrax-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//anthrax-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments